Published in PLoS One on August 17, 2012
T-cell immunophenotyping distinguishes active from latent tuberculosis. J Infect Dis (2013) 1.18
Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. BMC Infect Dis (2015) 0.81
Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis. Clin Vaccine Immunol (2014) 0.80
Tuberculosis Biomarkers: From Diagnosis to Protection. Infect Dis Rep (2016) 0.80
Heparin-binding haemagglutinin, a new tool for the detection of latent Mycobacterium tuberculosis infection in hemodialysis patients. PLoS One (2013) 0.79
Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection. Clin Vaccine Immunol (2014) 0.77
Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda. J Acquir Immune Defic Syndr (2016) 0.77
Long-incubation-time gamma interferon release assays in response to purified protein derivative, ESAT-6, and/or CFP-10 for the diagnosis of Mycobacterium tuberculosis infection in children. Clin Vaccine Immunol (2013) 0.77
Association of quantitative interferon-γ responses with the progression of naturally acquired Mycobacterium bovis infection in wild European badgers (Meles meles). Immunology (2015) 0.76
Involvement of methylated HBHA expressed from Mycobacterium smegmatis in an IFN-γ release assay to aid discrimination between latent infection and active tuberculosis in BCG-vaccinated populations. Eur J Clin Microbiol Infect Dis (2017) 0.75
Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med (2008) 9.49
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol (2009) 8.13
Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2011) 5.34
The population dynamics and control of tuberculosis. Science (2010) 5.08
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J (2009) 3.16
Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol (2002) 2.83
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77
Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med (2010) 2.67
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J (2010) 2.56
Eliminating latent tuberculosis. Trends Microbiol (2009) 2.47
The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med (2007) 2.39
Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med (2007) 1.96
Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. Clin Vaccine Immunol (2007) 1.59
Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis (2002) 1.50
Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med (2004) 1.47
Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One (2007) 1.36
Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol (2010) 1.32
A dynamic reinfection hypothesis of latent tuberculosis infection. Infection (2009) 1.29
Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J (2009) 1.27
Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol (2010) 1.25
The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun (2004) 1.17
Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect (2005) 1.13
Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron (1996) 1.10
Tuberculosis in maintenance dialysis patients. Nephron (2001) 1.05
Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect (2009) 1.05
Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS One (2011) 1.01
Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans. Am J Respir Crit Care Med (2010) 0.95
Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. J Infect Dis (2005) 0.95
Diagnosis of tuberculosis in dialysis patients: current strategy. Clin J Am Soc Nephrol (2010) 0.92
Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr Metab Immune Disord Drug Targets (2008) 0.91
Drugs for preventing tuberculosis in HIV infected persons. Cochrane Database Syst Rev (2000) 0.91
Boosting BCG to protect against TB. Expert Rev Respir Med (2010) 0.85
High rates of tuberculosis in end-stage renal failure: the impact of international migration. Emerg Infect Dis (2002) 0.83
Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 12.53
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol (2005) 4.52
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
Linkage disequilibrium between minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area. Mol Microbiol (2003) 3.31
Genotyping of the Mycobacterium tuberculosis complex using MIRUs: association with VNTR and spoligotyping for molecular epidemiology and evolutionary genetics. Infect Genet Evol (2003) 3.20
Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog (2008) 3.10
Assessment of an optimized mycobacterial interspersed repetitive- unit-variable-number tandem-repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. J Clin Microbiol (2006) 3.08
Structure of the membrane protein FhaC: a member of the Omp85-TpsB transporter superfamily. Science (2007) 3.07
Stability of variable-number tandem repeats of mycobacterial interspersed repetitive units from 12 loci in serial isolates of Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.77
Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study. Eur J Gastroenterol Hepatol (2005) 2.49
The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med (2007) 2.39
Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) (2010) 2.33
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine (2005) 2.31
Molecular typing of Mycobacterium tuberculosis by mycobacterial interspersed repetitive unit-variable-number tandem repeat analysis, a more accurate method for identifying epidemiological links between patients with tuberculosis. J Clin Microbiol (2005) 2.08
Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol (2005) 2.08
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol (2004) 2.06
Use of mycobacterial interspersed repetitive unit-variable-number tandem repeat typing to examine genetic diversity of Mycobacterium tuberculosis in Singapore. J Clin Microbiol (2004) 2.05
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 1.99
Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med (2007) 1.96
Nanoscale mapping and functional analysis of individual adhesins on living bacteria. Nat Methods (2005) 1.91
Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med (2008) 1.91
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. Vaccine (2010) 1.88
CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest (2010) 1.79
Multilocus variable-number tandem repeat typing of Mycobacterium ulcerans. J Clin Microbiol (2005) 1.77
Predominance of ancestral lineages of Mycobacterium tuberculosis in India. Emerg Infect Dis (2006) 1.75
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) (2005) 1.73
The crystal structure of filamentous hemagglutinin secretion domain and its implications for the two-partner secretion pathway. Proc Natl Acad Sci U S A (2004) 1.69
Tuberculin skin test and in vitro assays provide complementary measures of antimycobacterial immunity in children and adolescents. Chest (2009) 1.68
Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat Genet (2013) 1.67
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One (2009) 1.56
Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med (2014) 1.56
Ppm1, a novel polyprenol monophosphomannose synthase from Mycobacterium tuberculosis. Biochem J (2002) 1.54
A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest (2005) 1.54
Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis (2002) 1.50
Vaccines in a hurry. Vaccine (2009) 1.49
Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol (2004) 1.48
Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol (2003) 1.48
Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med (2004) 1.47
EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol Microbiol (2004) 1.46
Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl) (2001) 1.44
Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol Cell (2004) 1.41
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2010) 1.41
Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med (2009) 1.38
Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci U S A (2002) 1.37
Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis (2010) 1.37
Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. PLoS One (2007) 1.36
Mycolic acid biosynthesis and enzymic characterization of the beta-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosis. Biochem J (2002) 1.35
Assessing the serodiagnostic potential of 35 Mycobacterium tuberculosis proteins and identification of four novel serological antigens. J Clin Microbiol (2005) 1.32
Comparison of different standards for real-time PCR-based absolute quantification. J Immunol Methods (2010) 1.31
Secretion signal of the filamentous haemagglutinin, a model two-partner secretion substrate. Mol Microbiol (2006) 1.30
The forest behind the tree: phylogenetic exploration of a dominant Mycobacterium tuberculosis strain lineage from a high tuberculosis burden country. PLoS One (2011) 1.30
Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microbes Infect (2006) 1.29
Identification and structural characterization of an unusual mycobacterial monomeromycolyl-diacylglycerol. Mol Microbiol (2005) 1.29
Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. Eur J Immunol (2006) 1.28
Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol (2003) 1.27
Role of adhesin release for mucosal colonization by a bacterial pathogen. J Exp Med (2003) 1.26
Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog (2006) 1.26
Transient requirement of the PrrA-PrrB two-component system for early intracellular multiplication of Mycobacterium tuberculosis. Infect Immun (2002) 1.24
Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) (2006) 1.21
High heritability of antimycobacterial immunity in an area of hyperendemicity for tuberculosis disease. J Infect Dis (2010) 1.21
Mycobacterium tuberculosis with disruption in genes encoding the phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates reduced in vivo virulence. Infect Immun (2005) 1.18
Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol (2010) 1.17
Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS (2009) 1.17
Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae. Presence of unusual components with alpha 1,3-mannopyranose side chains. J Biol Chem (2002) 1.17
The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun (2004) 1.17
Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med (2009) 1.16
Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology (2004) 1.15
Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect (2005) 1.13
Surface anchoring of bacterial subtilisin important for maturation function. Mol Microbiol (2003) 1.13
Temperature-induced changes in the cell-wall components of Mycobacterium thermoresistibile. Microbiology (2002) 1.12
Channel properties of TpsB transporter FhaC point to two functional domains with a C-terminal protein-conducting pore. J Biol Chem (2005) 1.12
Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine (2002) 1.12
Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol (2007) 1.11
Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem (2003) 1.11
Immunity against HIV/AIDS, malaria, and tuberculosis during co-infections with neglected infectious diseases: recommendations for the European Union research priorities. PLoS Negl Trop Dis (2008) 1.10
Overrepresentation of a gene family encoding extracytoplasmic solute receptors in Bordetella. J Bacteriol (2003) 1.09
In vivo interaction between the polyprenol phosphate mannose synthase Ppm1 and the integral membrane protein Ppm2 from Mycobacterium smegmatis revealed by a bacterial two-hybrid system. J Biol Chem (2002) 1.07
Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications. Transpl Int (2007) 1.07
Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun (2002) 1.05
TB subunit vaccines--putting the pieces together. Microbes Infect (2005) 1.05
Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii: novel structural features and apoptosis-inducing properties. J Biol Chem (2003) 1.05
Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect (2009) 1.05
Enhanced bacterial virulence through exploitation of host glycosaminoglycans. Mol Microbiol (2002) 1.03
Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest. Eur J Emerg Med (2007) 1.02
Diagnosis of latent tuberculosis infection in healthy young adults in a country with high tuberculosis burden and BCG vaccination at birth. BMC Res Notes (2012) 1.02
Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status. Eur J Immunol (2010) 1.02
The periplasmic binding protein of a tripartite tricarboxylate transporter is involved in signal transduction. J Mol Biol (2005) 1.01